ALLERJECT 0.15 mg
Intended for patients who weigh 15 to 30 kg or 33 to 60lbs
Indications and clinical use:
ALLERJECT 0.3 mg (0.3 mL epinephrine injection, USP) and ALLERJECT 0.15 mg (0.15 mL epinephrine injection, USP) are indicated for the emergency treatment of anaphylactic reactions in patients who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions. Selection of the appropriate dosage strength is determined according to patient body weight. ALLERJECT is intended for immediate self-administration for the emergency treatment of severe allergic reactions (Type I). Following treatment of anaphylaxis, the patient must seek immediate medical attention.
Contraindications:
No absolute contraindications.
Relevant warnings and precautions:
In conjunction with administration, patients should seek appropriate medical care
More than two sequential doses of epinephrine should only be administered under direct medical supervision
Only inject into the outer thigh
Caregivers should hold the leg of young children firmly in place and limit movement prior to and during injection
Rare cases of serious infections at the injection site have been reported
Avoid use in patients with cardiogenic, traumatic or hemorrhagic shock, cardiac dilation, cerebral arteriosclerosis; use with caution in patients with cardiac arrhythmias, coronary artery or organic heart disease, hypertension or hyperthyroidism
Use with caution in patients with diabetes
Avoid use in patients with organic brain damage; use with caution in patients with Parkinson’s disease
Avoid use in patients with narrow-angle glaucoma
Use with caution in patients with concomitant asthma
Use with caution in patients with sulfite sensitivity
